

InsuLine is gearing up towards Sales in Germany
InsuLine announces the appointment of Andreas
Pfützner M.D. Ph.D. to Medical Director Europe
and an agreement on a clinical study for
reimbursement with the IKFE Institute

Dr. Pfützner previously served in executive medical positions in companies such as: Bidel Inc., Mannkind Corporation and Medtronic Minimed Inc. He has broad experience in design and management of clinical studies and is considered a key opinion leader in Germany.

Israel, Petach Tikva, January 8, 2012 – InsuLine Medical, a technology development, production and marketing company in the field of products designed to improve the effectiveness of insulin therapy, today announced that Andreas Pfützner has joined its fully owned subsidiary, InsuLine Medical GmbH, as Medical Director for Europe. In addition, InsuLine has signed an agreement with the IKFE Institute headed by Dr. Pfützner for a clinical study for reimbursement in Germany. The study has not yet started.

Ron Nagar, InsuLine CEO: “We welcome Dr. Pfützner on board and wish him luck in this position. Dr. Pfützner will broaden our management capability as we gear up to reach our goals. Dr. Pfützner has broad and impressive experience in the design and management of clinical studies, helping bring new products to market. He has served in a broad line of executive clinical roles in leading companies in our market. He will bring additional credibility to our studies and products among the European medical community and especially in Germany. In his role in InsuLine, Dr. Pfützner will manage the clinical studies we currently perform in Germany, and future studies we will perform in Europe. He will

present the medical and economic benefits that our products bring to patients, physicians and payers, to assist in their wide adoption”.

Elmar Schaefer, Managing Director of InsuLine GmbH: “Dr. Pfützner has a reputation among key opinion leaders and health insurer decision makers in Germany. We believe that he can assist the company in reaching its goals for 2012 and expanding its activity throughout Europe in the future. This is definitely a good start for the new year.”

Prof. Dr. Pfützner, M.D., Ph.D. served previously as Vice President and Chief Medical Officer for Europe at Bidel Inc.; Senior Vice President of Medical and Regulatory Affairs at Pharmaceutical Discovery Corporation (now MannKind Corporation). He has served as Vice President for Europe, Medical and Marketing at MiniMed, Inc.; Clinical Research Physician at Fournier Pharma and Eli Lilly, Germany. He serves as Member of the Scientific Advisory Board at Imvion Therapeutics Inc., Bidel Inc and Unomedical, since 2000. Prof. Dr. Pfützner serves as Professor of Applied Clinical Research at University of Applied Sciences Rheinbach. He has more than 300 international publications, abstracts and scientific presentations on AIDS research, diabetes and endocrinology. Prof. Dr. Pfützner holds an M.D. from University of Mainz, Germany and a Ph.D. from Rocheville University.

About IKFE:

The Institute for Clinical Research and Development in Mainz (IKFE GmbH) was founded by Prof. Dr. Andreas Pfützner (MD, PhD) and partners in 1998. IKFE GmbH offers complete clinical trial services world-wide, tailored to the special needs of pharmaceutical customers. It is a full-service development partner, supporting companies as they take their new products from research to market.

IKFE offers first class services in both the area of clinical research and scientific marketing. It specializes in the planning and support of pharmaceutical product development and in the organization and performance of scientific training programs for managers, sales representatives and other customers. Its key strength is extensive scientific know-how in the areas of diabetes, endocrinology and cardiovascular disease, as well as knowledge of related markets.